BioSpace News Archive

Drug Development

Researchers Continue to Develop Antivirals for Ebola, Zika, Other Infectious Diseases

Ebola cases, as well as cases of other significantly lethal viral outbreaks that have occurred has spurred researchers to focus on the development of antivirals that can treat the illnesses.

July 2, 2018
·
4 min read
·
Alex Keown
Biotech Beach

Virtual Reality: A Potential New Tool in Healthcare and Therapy R&D

Andrew Huberman, researcher in the Stanford University Department of Neurobiology, is taking an unusual approach to investigating possible treatments for glaucoma and anxiety disorders—virtual reality.

July 2, 2018
·
5 min read
·
Mark Terry
Deals

Rare Cancer Challenge: Genomic Screening and Clinical Trials

Both “rare cancers” and “sub-populations of cancers” present a challenge to companies conducting clinical trials—finding enough patients for those trials.

July 2, 2018
·
4 min read
·
Mark Terry
FDA

ReCor Medical Announces FDA Approval Of IDE For Pivotal Study Of Paradise® Ultrasound Denervation System For Treatment Of Hypertension

ReCor expects to initiate enrollment in RADIANCE-II in October of this year.

July 2, 2018
·
2 min read
Toyoda Gosei and EBM Corporation Develop a Prototype “Super BEAT” Medical Simulator Using e-Rubber

Surgical training simulator can reproduce the beating of the heart with extreme accuracy.

July 2, 2018
·
3 min read
Business

TSG Opens Paris Office

This key initiative underlines its continued focus on key European markets, in particular, France, Germany and Spain.

July 2, 2018
·
3 min read
Pharm Country

LYNPARZA® (olaparib) Approved in Japan for BRCA-Mutated Metastatic Breast Cancer

LYNPARZA is the First and Only PARP Inhibitor Approved for Use Beyond Ovarian Cancer

July 2, 2018
·
15 min read
Business

Takeda Global Headquarters Grand Opening

Takeda holds the grand opening of Takeda Global Headquarters in Nihonbashi, Tokyo, Japan.

July 2, 2018
·
4 min read
Drug Development

New Analysis of Rekovelle® Data Further Supports Use of AMH to Personalise Fertility Treatment

Rekovelle’s unique dosing algorithm, which is based on a woman’s anti-Müllerian hormone (AMH) level and body weight, is designed for predictable ovarian response

July 2, 2018
·
10 min read
Business

Invitation - Presentation of Sobi’s Q2 2018 Results

The event will be hosted by Sobi’s CEO and President, Guido Oelkers, and the presentation will be held in English.

July 2, 2018
·
2 min read